The study was published in October in the Journal of Clinical Oncology. It found that overall Imfinzi was well tolerated and safety was consistent with previous trials, according to a June 17 news release from AstraZeneca.
Endometrial cancers that are mismatch repair deficient are often seen in 25% to 30% of patients, according to a study published in the International Journal of Gynecological Cancer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
